Tango Therapeutics, Inc.
NASDAQ:TNGXBiotechnology
Healthcare
$21.89 -10.03%
-$3.24 today
- Market cap
- $3.71B
- Beta
- 1.19
- P/E (TTM)
- -38.9
- EPS (TTM)
- -$0.75
52W Low $4.60High $34.39
Volume 2.75M
Average 3.67M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$138.89M
FY 2025 · Annual
Investing Cash Flow
-$40.87M
FY 2025 · Annual
Financing Cash Flow
$222.50M
FY 2025 · Annual
+366.8% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (58.24M) | (108.18M) | (101.74M) | (130.3M) | (101.59M) |
| Depreciation & Amortization | 897K | 1.61M | 2.42M | 2.5M | 2.28M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.83M | 14.23M | 19.08M | 28.9M | 26.43M |
| Change in Working Capital | (11.35M) | (18.49M) | (37.97M) | (31.75M) | (67.2M) |
| Accounts Receivables | 0 | 0 | 2M | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.23M | 1.1M | (1.71M) | (1.18M) | (825K) |
| Other Working Capital | (12.58M) | (19.59M) | (38.26M) | (30.56M) | (66.37M) |
| Other Non-Cash Items | 1.32M | 1.75M | 234K | (849K) | 1.2M |
| Operating Cash Flow | (59.53M) | (109.08M) | (117.98M) | (131.5M) | (138.89M) |
| Capital Expenditures | (1.84M) | (7.69M) | (1.53M) | (754K) | (1.05M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (372.36M) | (208.5M) | (310.57M) | (240.89M) | (264.46M) |
| Sales of Investments | 190.76M | 242.6M | 353.53M | 327.77M | 224.64M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (183.43M) | 26.4M | 41.43M | 86.13M | (40.87M) |
| Debt Repayment | 342.11M | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 80.02M | 41.72M | 222.54M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (14.78M) | 1.62M | 2.39M | 5.94M | (36K) |
| Financing Cash Flow | 357.33M | 1.62M | 82.41M | 47.66M | 222.5M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 114.36M | (81.07M) | 5.85M | 2.29M | 42.75M |
| Free Cash Flow | (61.36M) | (116.77M) | (119.51M) | (132.26M) | (139.93M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$101.6M
+ D&A$2.3M
+ Stock-Based Comp$26.4M
+ Deferred Tax$0
- Working Capital-$67.2M
+ Other Non-Cash$1.2M
= Operating Cash Flow-$138.9M
- Capex-$1.0M
= Free Cash Flow-$139.9M
Analysis
FY2025 free cash flow is -$139.9M. FCF conversion is 137.7% of net income. Operating cash flow was -$138.9M, with capex of -$1.0M. The largest bridge item is Working Capital at -$67.2M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 6, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 4, 2026 |
Does TNGX generate free cash flow?
Tango Therapeutics, Inc. (TNGX) generated -$139.93M of free cash flow in fiscal 2025.
How much operating cash flow does TNGX produce?
Operating cash flow was -$138.89M, before capital expenditures of $1.05M.
Continue the stock analysis
Jump to another research area for this company.